Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Elimination of 14C-Perampanel in Healthy Males
NCT02116907Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2014
- Primary completion
- Jul 2014
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of perampanel in epilepsy, sponsored by Eisai Co., Ltd. Primary endpoints: Mass balance recovery of 14C at 14 weeks, Maximum observed concentration at 14 weeks and 5 more. Started May 2014; status: completed.
02
Drugs
perampanel
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02116907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02116907.